Alle Fälle anzeigen
UPC APP 11680/2025
—·EP2493466: NOVEL ANTITUMORAL USE OF CABAZITAXEL
- Verfahrensdetails
- Status—VerfahrensartVerfahrensantragKategorieRücknahmeanträge
- Parteien
- Kläger
- Sanofi Mature IP
- Sanofi Winthrop Industrie
- Sanofi-Aventis France
- Sanofi-Aventis GmbH
- Sanofi Belgium
- Sanofi-Aventis Deutschland GmbH
- Sanofi S.r.l.
- Sanofi B.V.
- Sanofi - Produtos Farmaceuticos Lda
- Sanofi AB
- Sanofi A/S
Vertreter: Frédéric Chevallier (Herbert Smith Freehills Kramer LLP)Beklagte- STADAPHARM GmbH
- STADA Arzneimittel AG
- STADA Nordic ApS
- Medac Gesellschaft für klinische Spezialpräparate m.b.H.
Vertreter: Daniel Hoppe (Preu Bohlig & Partner); Alexander Eisenführ (Uexkull + Stolberg) - Division
- Munich LD
- Richter
- Matthias Zigann · Presiding Judge / Judge-Rapporteur
- Alima Zana · Legally Qualified Judge
- Tobias Pichlmaier · Legally Qualified Judge
- Carola Wagner · Technically Qualified Judge
- Technology
- Pharmaceutical & Medical
- Sprache
- —
- Erste Entscheidung
- 19. März 2025
Entscheidungen
- 2025-03-19Application Rop 265
Procedural order by Munich Local Division (UPC_CFI_146/2024, 26 March 2025) granting Medac's application to withdraw its third-party access application, ordering deletion of a confidential Sanofi letter that Medac had uploaded without authorisation, imposing the deletion costs on Medac, and issuing a formal warning to Medac's representative for negligent conduct in uploading a privileged document. The court declined to award costs in the R.262(1)(b) application.
Rechtsfragen:Withdrawal of application (R. 265 RoP)Professional conduct / privilege breach (R. 290.2 RoP, Code of Conduct)Deletion of uploaded document (CMS)Costs in R.262(1)(b) proceedings
Dokumente
- 8BAB8521B6B4674E3BB1E57679069DD4_en.pdf2025-03-19EN